Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1982 1
1983 2
1984 2
1985 6
1986 9
1987 4
1988 4
1989 4
1990 5
1991 2
1992 5
1994 3
1995 1
1996 5
1997 4
1998 4
1999 4
2000 3
2001 2
2002 2
2003 3
2005 3
2006 4
2007 2
2008 10
2009 3
2010 2
2011 1
2012 1
2013 6
2014 2
2015 3
2016 14
2017 8
2018 9
2019 6
2020 14
2021 7
2022 7
2023 8
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. Nat Med. 2024. PMID: 39271844 Free PMC article. Clinical Trial.
SLC23A3 is a renal hypoxanthine transporter.
Hosoyamada M, Tomioka NH, Watanabe T, Yasuno N, Uchida S, Shibata S. Hosoyamada M, et al. Among authors: tomioka nh. Nucleosides Nucleotides Nucleic Acids. 2022;41(12):1279-1286. doi: 10.1080/15257770.2022.2028826. Epub 2022 Jan 30. Nucleosides Nucleotides Nucleic Acids. 2022. PMID: 35094660
Ultrafast olivine-ringwoodite transformation during shock compression.
Okuchi T, Seto Y, Tomioka N, Matsuoka T, Albertazzi B, Hartley NJ, Inubushi Y, Katagiri K, Kodama R, Pikuz TA, Purevjav N, Miyanishi K, Sato T, Sekine T, Sueda K, Tanaka KA, Tange Y, Togashi T, Umeda Y, Yabuuchi T, Yabashi M, Ozaki N. Okuchi T, et al. Among authors: tomioka n. Nat Commun. 2021 Jul 14;12(1):4305. doi: 10.1038/s41467-021-24633-4. Nat Commun. 2021. PMID: 34262045 Free PMC article.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T. Masuda J, et al. Among authors: tomioka n. J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126. J Immunother Cancer. 2023. PMID: 37709297 Free PMC article. Clinical Trial.
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, Yoshimoto M, Miura-Okuda M, Uchikawa R, Kato C, Shinozuka J, Akai S, Naoi S, Tomioka N, Nagaya N, Pang CL, Garvita G, Feng S, Shimada M, Kamata-Sakurai M, Aburatani H, Kitazawa T, Igawa T. Kamikawa T, et al. Among authors: tomioka n. J Immunother Cancer. 2024 Oct 14;12(10):e009563. doi: 10.1136/jitc-2024-009563. J Immunother Cancer. 2024. PMID: 39401967 Free PMC article.
Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study.
Jawdat O, Rucker J, Nakano T, Takeno K, Statland J, Pasnoor M, Dimachkie MM, Sabus C, Badawi Y, Hunt SL, Tomioka NH, Gunewardena S, Bloomer C, Wilkins HM, Herbelin L, Barohn RJ, Nishimune H. Jawdat O, et al. Among authors: tomioka nh. Sci Rep. 2024 Sep 17;14(1):21729. doi: 10.1038/s41598-024-72355-6. Sci Rep. 2024. PMID: 39289471 Free PMC article. Clinical Trial.
A steeply-inclined trajectory for the Chicxulub impact.
Collins GS, Patel N, Davison TM, Rae ASP, Morgan JV, Gulick SPS; IODP-ICDP Expedition 364 Science Party; Third-Party Scientists. Collins GS, et al. Nat Commun. 2020 May 26;11(1):1480. doi: 10.1038/s41467-020-15269-x. Nat Commun. 2020. PMID: 32457325 Free PMC article.
Vitamin C transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo investigations.
Toyoda Y, Miyata H, Uchida N, Morimoto K, Shigesawa R, Kassai H, Nakao K, Tomioka NH, Matsuo H, Ichida K, Hosoyamada M, Aiba A, Suzuki H, Takada T. Toyoda Y, et al. Among authors: tomioka nh. Pflugers Arch. 2023 Apr;475(4):489-504. doi: 10.1007/s00424-023-02792-1. Epub 2023 Feb 7. Pflugers Arch. 2023. PMID: 36749388 Free PMC article.
190 results